Online inquiry

IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15282MR)

This product GTTS-WQ15282MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Glioma Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15282MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11891MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ752MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ9001MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMA-638
GTTS-WQ1318MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ11889MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ13520MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRX002
GTTS-WQ743MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ1382MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-981
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW